@article{59cac3ccab084475859f42ff773d2f77,
title = "Phase II study of dasatinib in the treatment of head and neck squamous cell carcinoma (HNSCC)",
author = "Brooks, \{H. D.\} and B. Glisson and C. Lu and A. Sabichi and F. Johnson and L. Ginsberg and B. Bekele and V. Papadimitrakopoulou",
note = "6022 Background: Dasatinib is a potent inhibitor of src-family kinases, ephA2, PDGFR, Abl, and c-kit. A single-center, open-label, phase II trial was conducted to evaluate the safety, tolerability, pharmacokinetics (PK), and efficacy of dasatinib in recurrent or metastatic HNSCC.",
year = "2009",
month = may,
day = "20",
doi = "10.1200/JCO.2009.27.15\_SUPPL.6022",
language = "American English",
volume = "27",
journal = "Journal of Clinical Oncology",
}